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Pregabalin as a Neuroprotector after Spinal Cord Injury in Rats: 
Biochemical Analysis and Effect on Glial Cells 
As one of trials on neuroprotection after spinal cord injury, we used pregabalin. After 
spinal cord injury (SCI) in rats using contusion model, we observed the effect of pregabalin 
compared to that of the control and the methylprednisolone treated rats. We observed 
locomotor improvement of paralyzed hindlimb and body weight changes for clinical 
evaluation and caspase-3, bcl-2, and p38 MAPK expressions using western blotting. On 
histopathological analysis, we also evaluated reactive proliferation of glial cells. We were 
able to observe pregabalin’s effectiveness as a neuroprotector after SCI in terms of the 
clinical indicators and the laboratory findings. The caspase-3 and phosphorylated p38 
MAPK expressions of the pregabalin group were lower than those of the control group 
(statistically significant with caspase-3). Bcl-2 showed no significant difference between 
the control group and the treated groups. On the histopathological analysis, pregabalin 
treatment demonstrated less proliferation of the microglia and astrocytes. With this animal 
study, we were able to demonstrate reproducible results of pregabalin’s neuroprotection 
effect. Diminished production of caspase-3 and phosphorylated p38 MAPK and as well as 
decreased proliferation of astrocytes were seen with the administration of pregabalin. This 
influence on spinal cord injury might be a possible approach for achieving neuroprotection 
following central nervous system trauma including spinal cord injury. 
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Numerous efforts to overcome the neurologic deficits after spi-
nal cord injury have been attempted, and have advanced our 
understandings of the pathophysiologic mechanisms after spi-
nal cord injury (SCI) (1-4). However, few clinical trials have been 
completed. Contemporary research on spinal cord injury has 
been performed in two ways. One is neuro-protection that is fo-
cused on limiting or ameliorating the secondary pathophysio-
logic mechanisms. The other is neuro-regeneration that is fo-
cused on overcoming an established SCI such as gliosis. We have 
focused on excitotoxicity as one of these efforts to reduce the 
secondary mechanism of SCI. Excitatory neurotransmitters such 
as glutamate and asparate rapidly increase and then fall follow-
ing SCI. Presynaptic release, disrupted neurons, axons and/or 
glial cells, and especially astrocytes and oligodendrocytes, have 
been suggested as sources of glutamate in the gray matter and 
white matter. These over-expressed excitatory amino acids can 
subsequently cause apoptosis of neurons and glia cells, and es-
pecially oligodendrocytes (2, 5-8). Alteration of the intracellular 
sodium and calcium, which is mediated by the N-methyl-D-as-
parate (NMDA) and α-amino-3-hydroxy-5-methylisoxazole-4-
propionate-kainate (AMPA-kainate) receptors subsequently 
produces cytotoxic edema, acidosis and activation of a number 
of enzymes, including phospholipase, protease and nuclease. 
These enzymes subsequently elicit the destruction of cellular 
structures and they initiate apoptosis (9). 
  Pregabalin is a drug that is used for controlling neurogenic 
pain in various clinical conditions, including diabetic neuropa-
thy, neuralgia and complex regional pain syndrome. Its chemical 
structure is similar to that of gamma-aminobutyric acid (GABA). 
However, it does not act like GABA and it does not bind to the 
GABA receptors. It is known that it binds at the α2δ subunit of 
the voltage-controlled calcium channels. Its potent binding at 
this site reduces Ca
2+ influx at the presynaptic nerve endings and 
therefore, it reduces the release of several neurotransmitters, in-
cluding glutamate and noradrenalin (10-12). In vivo and in vitro 
studies have demonstrated the effect of pregabalin on the release 
of glutamate (13). However, most of these studies were designed 
for assessing the effect on neuropathic pain and no experimen-
tal trials have been completed in traumatic SCI. Thus, we de-
signed an experiment to study the effect of pregabalin on trau-
matic SCI and hypothesized that pregabalin would act as a neu-
roprotector after spinal cord injury. In the previous study, we Ha K-Y, et al.  •  Pregabalin as a Neuroprotector after Spinal Cord Injury 
http://jkms.org   405 DOI: 10.3346/jkms.2011.26.3.404
demonstrated that pregabalin could improve neurologic out-
comes, reduce the apoptosis of neurons and oligodendrocytes 
and reduce the expression of activated microglia histologically 
(14). In the present study, we tried to elucidate the reproducibil-
ity of the previous results with respect to SCI and examined the 
anti-apoptotic and anti-inflammatory effects of pregabalin. 
  Caspase-3 is activated during apoptosis of many types of CNS 
cells, and its activation appears to be an important event in apop-
tosis in the central nervous system (15). In contrast, bcl-2 pro-
teins regulate the release of cytochrome C from mitochondria, 
the subsequent activation of caspase and ensuing apoptotic cell 
death. Bcl-2 and bcl-XL are representative anti-apoptotic pro-
teins in the family of bcl proteins (6, 15, 16). We examined the 
expressions of caspase-3 and bcl-2 to assess the anti-apoptotic 
effect of pregabalin. Secondarily, in order to investigate the anti-
inflammatory effects of pregabalin, we examined p38 mitogen-
activated protein kinase (p38 MAPK) expression. p38 MAPK is 
a member of the MAPK family, and is known to be a potent reg-
ulator of the expression of inflammatory factors such as TNF-
alpha, interleukin (IL)-1, IL-6 etc. (17-19). Finally, we histopath-
ologically investigated the effect of pregabalin on the activation 
of glial cells, especially astrocytes and microglia. As the previous 
studies have reported, the proliferation of astrocytes and mi-
croglia is one of the key features in the secondary injury mecha-




A total of 50 adult male Sprague-Dawley rats (body weights; 250-
300 g each) were used in this study. They were kept under stan-
dardized conditions (4 rat/cage, 20°C-24°C, 45%-65% humidity, 
a 12 hr of daily light) and given free access to food and water 
throughout the study. Rats were randomly assigned to one of 
the following four groups before operation; the control group 
(Group I, n = 15, SCI alone), the sham operated group (Group 
II, n = 5, laminectomy only without SCI), the methylpredniso-
lone (MP) treated group (Group III, n = 15, SCI followed by in-
traperitoneal injection of methylprednisolone), and the prega-
balin (GP) treated group (Group IV, n = 15, SCI followed by in-
traperitoneal injection of pregabalin).
Operation technique 
The rats were anesthetized with ketamine (50 mg/kg) and rom-
pun (2 mg/kg, intraperitoneal). Their backs were shaved and 
then sterilized with antiseptic betadine. Lamincetomies were 
performed T9 after exposure of the paravertebral muscles from 
T8-10. All the spinal contusions were induced by 25 g-cm con-
tusion using the Multicenter Animal Spinal Cord Injury Study 
(MASCIS) impactor (drop from 2.5 cm height with a rod weigh-
ing 10 g). The 25 g-cm lesion was chosen to evaluate the neuro-
protection effect of the experimental trials in severe SCI and the 
rats would have insufficient motor recovery to ambulate over 
several weeks. Postoperatively, 5 mg gentamycin was adminis-
trated intramuscularly. The postoperative care procedures in-
volved providing the rat with drinking water in the cage as well 
as both softened rat chow and regular pellets placed directly in 
the cage. The rat’s bladders were emptied manually twice a day 
during this experiment. All of surgical interventions and the pre-
surgical and postsurgical animal care were provided in accor-
dance with the Laboratory Animal Welfare Act and the Guide-
lines and Policies for Rodent Survival Surgery, as provided by the 
Animal Studies Committee of the Catholic University of Korea 
(IACUC approval No. 2009-0086-01). 
Pharmacological administration 
In group III, 30 mg/kg MP was administered intraperitoneally 
at 30 min, 12, 24, and 48 hr after the contusion. In group IV, 30 
mg/kg pregabalin (Pfizer Pharmaceuticals, New York, NY, USA) 
was administered intraperitoneally at 30 min, 12, 24, and 48 hr 
after contusion. We followed the previous experiment dosage of 
pregabalin. It is similar to the clinical dosage that is commonly 
used for neuropathic pain (40-80 mg/kg/d).
Behavioral assessments
Motor function score
A motor function scale described by Gale et al. (20) was used to 
evaluate the rats’ motor function. The animals were allowed to 
move freely in an open field. An observer, who was blinded to the 
treatments the rats received, observed the rats for at least 1 min 
each and recorded movements in the hip, knee and ankle joints 
daily. All rats in the experimental groups were observed until 
sacrifice (postoperative 7 days).
Inclined plane task
All the rats were assessed using a second behavioral task, the 
inclined plane, which tests an animal’s ability to maintain its po-
sition on a board raised in 5° increments and so it can be used 
as an index of hind limb strength. The maximum angle at which 
a rat is able to maintain its position for at least 5 sec constitutes 
the inclined plane score. The rats were tested on the postopera-
tive 7th day before sacrifice.
Body weight changes
The body weights were examined for each rat. The differences 
between preoperative weight and weight 7th day post-injury 
were calculated.
Tissue preparation
On postoperative day 7, all the rats were killed via deep anesthe-
sia using intraperitoneal injections of ketamine and rompun. Ha K-Y, et al.  •  Pregabalin as a Neuroprotector after Spinal Cord Injury 
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For immunoflurorescence staining, 2 rats in the sham group and 
5 rats in the other groups were randomly selected and then trans-
cardiac perfusion was done for these rats with 100 mL of buff-
ered saline followed by 500 mL of 4% paraformaldehyde (pH 
7.4). We obtained a 1.5 cm segment of perfused spinal cord that 
encompassed the contusion site. The specimens were fixed in 
cold 4% paraformaldehyde overnight, incubated in 30% sucrose 
solution at room temperature for 4 hr, and then stored at -70°C. 
All remaining rats (3 rats in the sham and 10 rats in the other 
groups) were used for protein analysis. As soon as the rats were 
sacrificed, 3 cm spinal cord segments centered on the epicenter 
of the injury were dissected, removed quickly and stored at -80°C. 
Immunofluorescence staining
The tissue blocks were cut into 10 μm sections transversely to 
the long axis of the spinal cord. The sections were mounted on 
gelatin-coated slides. The mounted sections were then rinsed 
three times 10 min at a time with phosphate buffered saline 
(PBS), followed by blocking with 0.15% Triton X-100 and 5% 
normal horse serum (NHS) in 0.1 mM PBS for 30 min. The sec-
tions were next exposed to mouse monoclonal antibody GFAP 
(Calbiochem, Darmstadt, Germany), which is a specific astro-
cyte marker, at a dilution 1:100 in 0.1M PBS +0.15% Triton X-100 
+1% NHS. The next day, the sections were incubated with a di-
lution of the secondary antibody, FITC conjugated anti-mouse 
IgG (Jackson ImmunoResearch, West Grove, PA, USA) for fluo-
rescence. After 4 hr exposure, the slides were rinsed with 0.1 mM 
PBS five times, covered and then stored in a freezer. The slides 
were then thawed and photographed with a confocal analysis 
system (Olympus Microscope Confocal/Image Analysis system, 
Tokyo, Japan). The fluorescent light green cells were counted in 
a 75 × 250 μm area centered at the epicenter of the injured spinal 
cord. The other immunofluorescence staining was performed 
for identifying the microglia by using the monoclonal antibody 
OX-42 (1:500, Calbiochem), which labels the complement type 
3 receptor on the microglia and macrophages. FITC was also 
used for fluorescence. 
Quantification of the immunofluorescent cells
Morphometric analysis of the positively fluorescent cells was 
performed under high-power magnification (× 200) in a blind-
ed fashion. On each slide, six fields were randomly selected and 
in order to eliminate bias from hemorrhage and necrosis, cells 
were counted at the peripheral margin of the cystic lesions. The 
mean numbers of each specimen were recorded and the mean 
numbers of each group were compared. To exclude the false 
positive counting of immunofluorescent cells, the cells which 
were coincident with DAPI were considered as positive cells. 
Western blot analysis
The spinal cord samples were homogenized on ice in RIPA buf-
fer (150 mM NaCl, 50 mM Tris-HCl [pH 7.4], 2 mM EDTA, 1% 
NP-40, 10 mM NaF, 1 mM Na3VO4, 10 mM sodium pyrophos-
phate, 1 mM PMSF, 10 mg/mL aprotinin, 10 mg/mL leupeptin, 
and 0.1 mg/mL soybean inhibitor). The lysate was centrifuged 
at 15,000 rpm for 20 min at 4°C. Proteins were separated by SDS–
polyacrylamide gel electrophoresis and transferred to polyvinyl-
idene difluoride membrane (Hybond-P, Amersham Pharmacia 
Biotech, Buckinghamshire, UK). The membrane was blocked 
with 5% fat-free dry milk for 1 hr in Tris-buffered saline (0.1% 
Tween-20, 20 mM Tris-HCl, 137 mM NaCl, pH 7.4) and then it 
was incubated overnight at 4°C with the primary antibodies. The 
antibodies used for immunoblotting were as follows: anti-rabbit 
activated caspase-3 antibody (1:1,000; Cell Signaling Technolo-
gy, Danvers, MA, USA), anti-rabbit phosphorylated p-38 MAPK 
(1:1,000; Cell Signaling Technology), anti-rabbit p-38 MAPK (1: 
1,000; Cell Signaling Technology) and anti-mouse Bcl-2 (1:1,000; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA). After the mem-
branes were washed, they were incubated with secondary per-
oxidase-conjugated anti-rabbit or anti-mouse antibodies (Am-
ersham Pharmacia Biotech) that were diluted 1:2,000 in Tris-
buffered saline with 0.01% Tween 20. An antibody detection sys-
tem (ECL, Amersham Pharmacia Biotech) was used and the 
membranes were exposed to radiography film. The protein band 
intensities were quantified with a VDS densitometer (Amersham 
Pharmacia Biotech).
Statistical analysis
All the values in the figures and text are expressed as mean ± 
SEM. The results were analyzed by one-way ANOVA followed 
by a Bonferroni post-hoc test for multiple comparisons. A P val-




The time course of functional recovery, as measured by the Gale 
rating score, was recorded (Fig. 1). The results of the “motor func-
tion score” evaluation are presented as a mean value with SEM 
(Table 1). The mean motor function scores at post-injury day 7 
were 1.92 ± 0.2, 6 ± 0, 2.0 ± 0.3, and 3.17 ± 0.2 in group I to IV re-
spectively. On the statistical analysis, the mean motor function 
scores of each group had a statistically significant difference (P = 
0.01), which was tested for with a one-way ANOVA. The recov-
ery of hindlimb function in the GP group was superior to that of 
the control and the MP groups (P = 0.01). 
Inclined plane test
The results of the “inclined plane score” evaluation are present-
ed as a mean value with SEM. The mean inclined plane angles 
were 28.7 ± 1.5°, 46 ± 1.0°, 27.7 ± 1.5°, and 31.3 ± 0.8° in group I  Ha K-Y, et al.  •  Pregabalin as a Neuroprotector after Spinal Cord Injury 
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to IV respectively. On the statistical analysis, the mean inclined 
plane scores of each group had a statistical significance (P = 0.01). 
Comparing the GP group with the MP group, there was also sta-
tistical significance (P = 0.01). 
Body weights changes
Most of the injured rats, except the sham operated rats, suffered 
from loss of body weight during the observation period. The 
mean changes for the control group and the MP group are larg-
er than that for the GP group (P < 0.05, Table 1).
Effect of pregabalin on the caspase-3, bcl-2 and p38 MAPK 
expression
The relative optical densities for caspase-3 were 1.6 ± 0.16, 1.33 
± 0.02, 1.63±0.2, and 0.97 ± 0.05 in group I-IV, respectively (Fig. 
2A). The caspase-3 expression was significantly decreased in GP 
group compared to the control and MP groups (f = 3.97, P < 0.05, 
Bonferroni post hoc analysis, P < 0.05, n = 10). The relative opti-
cal densities for bcl-2 are 0.97 ± 0.27, 0.27 ± 0.04, 0.74 ± 0.17, and 
0.8 ± 0.26 in group I-IV, respectively (Fig. 2B). However, it revealed 
no statistical difference between groups (f = 0.52, P = 0.67). The 
relative optical densities for phosphorylated p38 MAPK are 0.52 
± 0.12, 0.25 ± 0.01, 0.39 ± 0.08, and 0.4 ± 0.08 in group I-IV, respec-
tively (Fig. 3). The control group tends to express higher levels 
phosphorylated p38 MAPK than the other groups. However, 
there was no statistically significant difference (f = 0.65, P = 0.58).
Activation of the astrocytes and microglia 
Except for the sham operated rats, the spinal cord of all the in-
jured groups demonstrates the abundant activation of astro-
cytes (Fig. 4). The number of GFAP positive cells was 47.3 ± 2.5, 
21.5 ± 3.7, 32.5 ± 5.2, and 29.3 ± 2.5 in group I-IV, respectively. 
The control group demonstrate a statistically significant increase 
in the number of the activated astrocytes compared to that of 
the other groups (P < 0.05). In most specimens, the activated 
astrocytes were located around the injured site and recruitment 
was also observed from the adjacent gray and white matter. The 
mean number of OX-42 positive cells in the × 200 magnified 
specimen was 21.2 ± 1.2, 5.3 ± 2.4, 18.6 ± 2.3, and 19.6 ± 1.5 in 
group I-IV, respectively. The injured group demonstrated a sig-
nificantly elevated number of activated microglia. However, there 
was no statistical difference among the injured groups (Fig. 5).
Fig. 2. (A) The effect of intraperitoneal pregabalin (30 mg/kg) on the expression of caspase-3 in contusive spinal cord injury. One-way ANOVA reveals significant differences 
between the groups for the expression of caspase-3 expression in the spinal cord tissue and the post hoc comparison (Bonferroni) test revealed that pregabalin treatment 
induced the least expression of caspase-3.This difference showed a statistical significance compared to the control group and the methylprednisolone treated group (P < 0.05, 
n = 10 for the experimental group, n = 3 for sham group). (B) The effect of intraperitoneal pregabalin (30 mg/kg) on the expression of bcl-2 in contusive spinal cord injury. 
One-way ANOVA test and post hoc analysis reveal no significant difference between the groups for the expression of bcl-2 expression in the spinal cord tissue (f = 0.52, P = 














Caspase-3 expression bcl-2 expression
Group Group
19 kDa 28 kDa Caspase-3 bcl-2
42 kDa 42 kDa β-actin β-actin
*
  Control  Sham  MP  GP   Control  Sham  MP  GP
Control Control Sham Sham MP MP GP GP
A B
Table 1. Behaviour assessments
Group I Group II Group III Group IV
Motor Function score 1.92 ± 0.2   6 2.0 ± 0.3 3.17 ± 0.2
Inclined plane test (°) 28.7 ± 1.5 46.0 ± 1.0 27.8 ± 1.5 31.2 ± 0.8
Body weight change -11.5 ± 5.0 37.2±11.0 -62.3 ± 3.7 3.75 ± 6.5
*The post-injury 7 days scores were assessed. (-) means loss of body weight.
Fig. 1. Motor scores for the each group. The rats in all the groups show a sequential 
recovery of hindlimb function. At the postoperative 7th day, the pregabalin treated 
group show a more significant recovery compared to that of the other groups. 
























GPHa K-Y, et al.  •  Pregabalin as a Neuroprotector after Spinal Cord Injury 
408   http://jkms.org DOI: 10.3346/jkms.2011.26.3.404
DISCUSSION
Many diverse approaches for neuroprotection are being attempt-
ed as details of the mechanisms of secondary injury after SCI 
have been disclosed in the last few years. Through our previous 
study, we were able to verify the possibility of pregabalin as a 
neuroprotector after SCI (14). In that study, we only presented 
the anti-apoptotic and anti-inflammatory effects by histopathol-
ogy. The present study used not only functional outcomes but 
also more detailed immunohistochemistry to demonstrate the 
feasibility of pregabalin on SCI. First, we analyzed the anti-apop-
totic and anti-inflammatory effects by measuring the expression 
of caspase-3, bcl-2 and p38 MAPK. These molecules are known 
to be key players in the processes of apoptosis and inflammation 
(4, 15, 16, 21). Following spinal cord injury, neurons and glial 
cells undergo apoptosis; and the subsequent demyelination by 
apoptosis of oligodendrocyte is a key feature of secondary spi-
nal cord injury. Previous studies have demonstrated that this 
phenomenon peaks at 48 hr and 7 days after SCI (1, 2, 15). And 
excitotoxicity is known to be one of the major pathomechanisms 
to elicit the apoptosis of the neuron and the supporting glial cells 

















  Control  Sham  MP  GP
Control Sham MP GP
Fig. 3. The effect of intraperitoneal injection of pregabalin (30 mg/kg) on the expres-
sion of phosphorylated p38 MAPK in contusive spinal cord injury. The values were 
examined on post-injury day 7. The methylprednisolone and pregabalin treatment 
groups demonstrate a reduced expression of phosphorylated p38 MAPK as compared 
to that of the control group. However, ANOVA indicated no statistically significant dif-
ference (f = 0.65, P = 0.58, n = 10 for the experimental group, n = 3 for the sham 








Fig. 4. Immunofluorescence detection of 
the activated astrocyte labeled with anti-
body GFAP. Abundant activation of astro-
cytes is observed in the most of the spe-
cimen of the injured groups. The control 
group demonstrate a higher number of 
activated astrocytes than that of the MP 
and the GP groups. The astrocytes are 
mostly located around the periphery of 
the injured site, and the astrocytes also 
show a tendency of recruitment from the 
surrounding gray and white matter (mag-
nification × 200, scale bar 20 µm).Ha K-Y, et al.  •  Pregabalin as a Neuroprotector after Spinal Cord Injury 







Fig. 5. Immunofluorescence detection of 
the activated microglia labeled with anti-
body OX-42. The injured group demon-
strates a significantly elevated number of 
activated microglia. However, there was no 
statistical difference among the injured 
groups (magnification × 200, scale bar 
20 µm).
axons and/or glial cells, and especially astrocytes and oligoden-
drocytes, have been suggested as sources of glutamate in the 
gray matter and white matter. And subsequently these over-ex-
pressed excitotoxic neurotransmitters can induce the apoptosis 
by means of the direct damage of the mitochondria and the in-
duction of apoptosis inducing enzymes including caspases. In 
this study, we observed a statistically significant reduction of cas-
pase-3 expression in the pregabalin-treated group. The reduced 
expression of caspase-3 in the pregabalin group might be relat-
ed to the pharmacologic action of this drug. Pregabalin may re-
duce extracellular glutamate concentration after SCI and this 
down-regulating effect of pregabalin was associated with rescu-
ing cells from excitotoxicity. When we first designed this experi-
ment, we decided to take the sample at the 7th day post-injury. 
This was based on the previous references that have demonstrat-
ed the apoptosis of neuronal damage after SCI persisted through 
the first week (2, 15). Although the present study demonstrated 
the statistical significant reduction of caspase-3 expression, we 
were not able to observe the significant differences in other pro-
teins that are also related to apoptosis pathway. However, if we 
evaluate more of the acute stage samples (for example 24 hr af-
ter injury), we look forward to finding more statistical significant 
differences. We also measured phosphorylated p38 MAPK. p38 
MAPK has been reported to have inflammation-modulating 
function at the level of transcription and translation (18, 19, 22). 
In the central nervous system, the glia, and mainly microglia, 
upregulate the expression and activation of p38 MAPK in patho-
logic conditions, and the subsequent activation of other cyto-
kines such as IL-1, IL-6, TNF-α, and COX-2 (17, 23, 24). In the 
present investigation, although not statistically significant, the 
pregabalin treated group showed lower expression of phosphor-
ylated p38 MAPK than that of the control group. This finding is 
further supported by the histologic differences noted with regard 
to the activation of microglia. During histopathologic evaluation, 
we focused on the observation of reactive astrocytosis and pre-
gabalin effects on it. Astrocytes have been shown to regulate of 
the extracellular level of glutamate in synapses. This scavenger 
action on overexpressed glutamate is exerted by excitatory ami-
no acid transporters (EAATs) and glutamine synthetase (25, 26). 
In response to injury in the central nervous system, astrocytes 
change their appearance and they undergo a characteristic hy-
pertrophy of their processes with the upregulation of interme-
diate filaments that are composed of glial fibrillary acid protein, 
vimentin and nestin. These changes are known as gliosis and Ha K-Y, et al.  •  Pregabalin as a Neuroprotector after Spinal Cord Injury 
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they are a suitable reaction to overcome the pathologic condi-
tion (25). Astrocyte proliferation after injury has been known to 
have both detrimental and beneficial effects (26, 27). Astrocyte 
scarring has long been considered as a major impediment to 
the regeneration of damaged axons. Chondroitin sulfate glyco-
proteins are well known key molecules in inhibiting the regen-
eration of axons (28). However, beneficial effects of astrocytes 
have recently been established as well. Astrocyte protective ac-
tions are exerted by restoring altered homeostasis (the ionic and 
neurotransmitter balance) and re-establishing the anatomical 
blood-brain barrier (29). At later stages, astrocytes can aid in re-
generation by production of a variety of cytokines such as TGF- 
β, glial cell line derived neurotrophic factor, β-FGF and VEGF 
(29, 30). Some of these growth factors can facilitate oligodendro-
cyte precursor migration, proliferation and differentiation (30). 
Taking these backgrounds of the astrocyte into account, we care-
fully hypothesize that pregabalin may reduce excitotoxicity and 
minimize the need for astrocytic clearance of glutamate during 
the acute pathologic condition of SCI. Because astrocytes can 
provide positive effects, however, it remains to be seen if the low-
er proliferation of astrocytes can provide long-term benefit. 
  In summary, we were able to get more promising results that 
might support the feasibility of pregabalin following SCI. Anti-
inflammatory and anti-apoptotic effects of pregabalin were re-
peatedly demonstrated by the histopathological and biochemi-
cal methods. Further studies are needed to determine the safe-
ty, ideal dosages, methods of administration and defining long-
term results. We are encouraged, however, that pregabalin might 
be another neuroprotective agent for the treatment of spinal cord 
injury.
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Pregabalin was used as a neuroprotective agent after spinal cord injury (SCI). Here we compared the effects of pregabalin with 
methylprednisolone. 50 rats were divided into four groups; the control group, the sham operated group, the methylprednisolone 
treated group, and the pregabalin-treated group. The pregabalin-treated group showed improved mean motor function score and 
the inclined plane score. Caspase-3 and phosphorylated p38MAPK expression of the pregabalin group were lower than that of the 
control group. Bcl-2 expression was not different between the control and the treated groups. In histopathological analysis, 
pregabalin treated group demonstrated less proliferation of microglia and astrocyte. The above data suggest neuroprotective 
effects of pregabalin.